Stay updated on Pembrolizumab Combo With Local Ablation in HCC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo With Local Ablation in HCC Clinical Trial page.

Latest updates to the Pembrolizumab Combo With Local Ablation in HCC Clinical Trial page
- Check2 days agoChange DetectedLocations section added for Lower Saxony, listing Hanover, Germany as a study site. The HHS Vulnerability Disclosure link in the footer was removed.SummaryDifference0.2%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedFooter shows Revision: v3.3.2 replacing v3.2.0. There are no changes to the study details, eligibility criteria, or results on the page.SummaryDifference0.1%

- Check38 days agoChange DetectedRemoved the site-wide funding/operating-status banner. The study details, eligibility criteria, and results information on this page remain unchanged.SummaryDifference0.4%

- Check52 days agoChange DetectedNo significant updates were detected on the page; the study details, inclusion criteria, and planned interventions remain as published. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check80 days agoChange DetectedCore content updated to reflect current operating status and official references; version bumped from v3.1.0 to v3.2.0.SummaryDifference2%

- Check87 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Combo With Local Ablation in HCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo With Local Ablation in HCC Clinical Trial page.